Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose
This study was undertaken to determine the maximum-tolerated doses of gemcitabine and cisplatin, each given weekly for 3 weeks with a 1-week rest. Patients less than 75 years of age were eligible if they had stage III/IV non-small-cell lung cancer (NSCLC), life expectancy > or = 12 weeks, hemoglo...
Saved in:
Published in | Journal of clinical oncology Vol. 14; no. 5; p. 1656 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.05.1996
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | This study was undertaken to determine the maximum-tolerated doses of gemcitabine and cisplatin, each given weekly for 3 weeks with a 1-week rest.
Patients less than 75 years of age were eligible if they had stage III/IV non-small-cell lung cancer (NSCLC), life expectancy > or = 12 weeks, hemoglobin level > or = 10 g/dL, granulocyte count > or = 2 x 10(9)/L, platelet count > or = 100 x 10(9)/L, hepatic enzymes < or = three times the upper limit of normal, and creatinine concentration < or = 130 mumoles/L. The starting doses for gemcitabine and cisplatin were 1,000 mg/m2 and 25 mg/m2 per week for 3 weeks. At dose level 2, cisplatin was increased to 30 mg/m2/wk for 3 weeks, and thereafter only gemcitabine was increased by 250 mg/m2/wk at each dose level to a maximum of 2,250 mg/m2/wk.
There were 33 men and 17 women, with a median age of 62 years. Pathology included adenocarcinoma in 35 patients, squamous in eight, large cell in six, and mixed histology in one. Sixteen patients had stage III and 34 had stage IV tumors. The median nadir granulocyte and platelet counts decreased with each dose level, but cycle 1 dose-limiting toxicity (DLT) in > or = two patients was not encountered in cycle 1, even at the highest dose level. Cumulative marrow toxicity was seen at all levels, which resulted in frequent dose reductions or omissions. A mathematic model of all toxicities over time suggested that dose level 4 (cisplatin 30 mg/m2/wk and gemcitabine 1,500 mg/m2/wk) would be the maximum dose at which grade 4 toxicity would be expected in < or = 33% of patients over four cycles. Of 47 assessable patients, 14 achieved a partial response (30%; confidence interval, 17% to 43%). The median duration was 16 weeks and the median survival time was 24 weeks (range, 3.5-64+).
Weekly gemcitabine and cisplatin are active against NSCLC, and the recommended phase II doses are 30 and 1,500 mg/m2/wk for 3 weeks, respectively. |
---|---|
AbstractList | This study was undertaken to determine the maximum-tolerated doses of gemcitabine and cisplatin, each given weekly for 3 weeks with a 1-week rest.
Patients less than 75 years of age were eligible if they had stage III/IV non-small-cell lung cancer (NSCLC), life expectancy > or = 12 weeks, hemoglobin level > or = 10 g/dL, granulocyte count > or = 2 x 10(9)/L, platelet count > or = 100 x 10(9)/L, hepatic enzymes < or = three times the upper limit of normal, and creatinine concentration < or = 130 mumoles/L. The starting doses for gemcitabine and cisplatin were 1,000 mg/m2 and 25 mg/m2 per week for 3 weeks. At dose level 2, cisplatin was increased to 30 mg/m2/wk for 3 weeks, and thereafter only gemcitabine was increased by 250 mg/m2/wk at each dose level to a maximum of 2,250 mg/m2/wk.
There were 33 men and 17 women, with a median age of 62 years. Pathology included adenocarcinoma in 35 patients, squamous in eight, large cell in six, and mixed histology in one. Sixteen patients had stage III and 34 had stage IV tumors. The median nadir granulocyte and platelet counts decreased with each dose level, but cycle 1 dose-limiting toxicity (DLT) in > or = two patients was not encountered in cycle 1, even at the highest dose level. Cumulative marrow toxicity was seen at all levels, which resulted in frequent dose reductions or omissions. A mathematic model of all toxicities over time suggested that dose level 4 (cisplatin 30 mg/m2/wk and gemcitabine 1,500 mg/m2/wk) would be the maximum dose at which grade 4 toxicity would be expected in < or = 33% of patients over four cycles. Of 47 assessable patients, 14 achieved a partial response (30%; confidence interval, 17% to 43%). The median duration was 16 weeks and the median survival time was 24 weeks (range, 3.5-64+).
Weekly gemcitabine and cisplatin are active against NSCLC, and the recommended phase II doses are 30 and 1,500 mg/m2/wk for 3 weeks, respectively. |
Author | Strack, T Schulz, M Cormier, Y Shepherd, F A Feld, R Burkes, R Crump, M |
Author_xml | – sequence: 1 givenname: F A surname: Shepherd fullname: Shepherd, F A organization: Department of Medicine, Toronto Hospital, Ontario, Canada – sequence: 2 givenname: R surname: Burkes fullname: Burkes, R – sequence: 3 givenname: Y surname: Cormier fullname: Cormier, Y – sequence: 4 givenname: M surname: Crump fullname: Crump, M – sequence: 5 givenname: R surname: Feld fullname: Feld, R – sequence: 6 givenname: T surname: Strack fullname: Strack, T – sequence: 7 givenname: M surname: Schulz fullname: Schulz, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8622085$$D View this record in MEDLINE/PubMed |
BookMark | eNotUEtOwzAQ9aKotIULICH5Agm2Y-fDDlV8iiqVBUjsqok9aY1sp4oTBEfilqTQzbzFvJ_enExCG5CQK85SLhi7eV5uUl5VecplqlKeq3xCZqzIRMLL7P2czGP8YIzLMlNTMi1zIVipZuTnZQ8R6YqaNmKCUYOD3raB9p0FR9uG7tBr20NtA1IIhmobD0dOoE3bUTCfEDQaOtZJogfnEo3OUTeEHdXHV3dLh4jN4ALGeDT00O9xPFZT3xp0dmT2LTXYY-ePKR6-rB980rcOO6gd_pW7IGcNuIiXJ1yQt4f71-VTst48rpZ360RnquwTOYLKBIqsKmrT5DXXKs9VkaGsmC4kQCNErTNTodQSClYBbwAlGm1GlRYLcv3vexhqj2Z76KyH7nt7mkz8AtPSczg |
CitedBy_id | crossref_primary_10_1023_A_1025464510639 crossref_primary_10_1097_00002820_199904000_00011 crossref_primary_10_1517_14656566_2_6_929 crossref_primary_10_1097_00001813_200006000_00002 crossref_primary_10_1016_S0169_5002_99_00033_1 crossref_primary_10_1023_A_1008384326701 crossref_primary_10_1200_JCO_1999_17_3_914 crossref_primary_10_1007_s00280_009_1020_y crossref_primary_10_1081_CNV_120001144 crossref_primary_10_1097_00000441_199812000_00008 crossref_primary_10_1016_S0169_5002_98_00069_5 crossref_primary_10_1016_S0147_0272_98_90010_1 crossref_primary_10_1097_00001813_200002000_00008 crossref_primary_10_1023_A_1011140818150 crossref_primary_10_1097_00001813_200302000_00004 crossref_primary_10_1200_JCO_2007_10_7078 crossref_primary_10_1016_S0002_9629_15_40451_3 crossref_primary_10_1634_theoncologist_2_3_127 crossref_primary_10_1002_cncr_10991 crossref_primary_10_1080_028418600430824 crossref_primary_10_2165_00003088_200039010_00002 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1200/JCO.1996.14.5.1656 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 8622085 |
Genre | Clinical Trial Journal Article Clinical Trial, Phase I |
GroupedDBID | --- .55 .GJ 08G 08P 0R~ 18M 29K 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 5VS 8F7 8WZ A6W AAKAS AAQOH AAQQT AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV ADZCM AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN BAWUL C45 CGR CS3 CUY CVF D-I DIK EBS ECM EIF EJD EX3 F5P F9R FBNNL FD8 FEDTE GX1 H13 HVGLF HZ~ IH2 IPNFZ J5H K-O KQ8 L7B LSO MJL N4W N9A NPM NTWIH O9- OK1 OVD OWW P2P QTD R1G RHI RIG RLZ RUC SJN SV3 TEORI TR2 TWZ UDS UHU VH1 VVN WH7 WOQ WOW X7M YCJ YFH YQY ZGI |
ID | FETCH-LOGICAL-c358t-4c35532e2397bdf6b1c566573e490c74aaf22bc3d9e4c4a709a1fae4edcd2e2c2 |
ISSN | 0732-183X |
IngestDate | Sat Sep 28 07:31:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c358t-4c35532e2397bdf6b1c566573e490c74aaf22bc3d9e4c4a709a1fae4edcd2e2c2 |
PMID | 8622085 |
ParticipantIDs | pubmed_primary_8622085 |
PublicationCentury | 1900 |
PublicationDate | 1996-05-01 |
PublicationDateYYYYMMDD | 1996-05-01 |
PublicationDate_xml | – month: 05 year: 1996 text: 1996-05-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 1996 |
References | 9164234 - J Clin Oncol. 1997 May;15(5):2172-4 |
References_xml | |
SSID | ssj0014835 |
Score | 1.7130146 |
Snippet | This study was undertaken to determine the maximum-tolerated doses of gemcitabine and cisplatin, each given weekly for 3 weeks with a 1-week rest.
Patients... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1656 |
SubjectTerms | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adult Aged Antimetabolites, Antineoplastic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Dose-Response Relationship, Drug Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Models, Theoretical |
Title | Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose |
URI | https://www.ncbi.nlm.nih.gov/pubmed/8622085 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFICtDgTaC4LBBOOi84D20rmkjpO0vKGKaUPaqEQn9W1KfGEVaVM1jbTxj_gd_DGOL23SbojLS1TFbuTkfDo-ts-FkLexYqzPpKCB0BHlIuI0S0SX9riOFWddXMyZE92z8_jkgn8aR-NW62fDa6laZh3x_c64kv-RKt5DuZoo2X-Q7PqheAN_o3zxihLG61_JeHiFc1D7tC2LUlFV4ud24nSlONAM_KqmAhf_mTElbQDbpJybPs67sD7_L2a0nKZ5Ts0-fjuvTCCuabI1JKtS6Sq3KtEcxtd5Xm0VHRtuVbSld6sx_rDXk2k1pcsiVwsXmFWUmw5HtRG8DswsZmJjg__LlfE-c373x40N12rxTW06Og7Q6p448NZm-WCBlNZ7vdKH-cW1D6FXfknIKKqb8Yam5g0io4baNSmE7pwPmCt1PfhsojJjnBY6UWe7M37J-dQSgqs7U7L0j41bGbp9yw7ZSXpGyZ6bDSN_kMV7rsbr6nV83BaO693tUe2SB_5ZW4sca-yMHpNHXkDwwSH3hLTUbI88PPN-GHvkcOgynt8cwagO4CuP4BCGdS70m6fkh0UUTmELUbCIQqGhgSggorBGFBBRWCEKm4iCQRQcou-hBtQ8sAYUVoDCsoA1oHALUDu4Z-Ti-ONocEJ9dRAqwqi3RL2CpnLIFEOLOpM6zroiMseIoeL9QCQ8TTVjmQhlX3HB0yTop12dKq6kkPgvwfbJPRy7ek6Ay0QZbyFciisepKqvZcJ1gN1RPlrGL8i-k8bl3KWAufRiOvhdw0uyW1P9itzXqHHUazRfl9kbC8gvkiOgTQ |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I+dose-escalation+trial+of+gemcitabine+and+cisplatin+for+advanced+non-small-cell+lung+cancer%3A+usefulness+of+mathematic+modeling+to+determine+maximum-tolerable+dose&rft.jtitle=Journal+of+clinical+oncology&rft.au=Shepherd%2C+F+A&rft.au=Burkes%2C+R&rft.au=Cormier%2C+Y&rft.au=Crump%2C+M&rft.date=1996-05-01&rft.issn=0732-183X&rft.volume=14&rft.issue=5&rft.spage=1656&rft_id=info:doi/10.1200%2FJCO.1996.14.5.1656&rft_id=info%3Apmid%2F8622085&rft_id=info%3Apmid%2F8622085&rft.externalDocID=8622085 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |